Participant flow



Baseline Characteristics

	Placebo, n = 38	**Lidocaine, n = 38**
Age (years)	38 ± 11 [21-62]	37 ± 14 [19-65]
Gender (n)		
Men	17	15
Women	21	23
Decease (n)		
Crohn	31	31
Colitis ulcerosa	7	7
BMI (kg/m^2)	25.2 ± 4,3 [18.4-34.2]	24. 2 ± 3,1 [18.3-30.7]
Duration of PSA (minutes)	33 ± 10 [18-59]	32 ± 10 [15-57]

Outcome measures:

Primary outcome:

	Placebo	Lidocaine	P value
Alfentanyl (mcgr)	868 ± 647	632 ± 519	0,08

Secondary outcome

	Placebo	Lidocaine	P value
Propofol: total dose (mg)	387 ± 106	349 ± 85	0.09
Postcolonoscopy pain (NRS >4) (n)	2	3	
PONV	0	0	

Adverse events:

	Placebo, n = 38	**Lidocaine, n = 38**
Oxygen desaturation SpO_2 < 92%	10 (26%)	8 (21%)
Hypotension mean RR < 60 mmHg	0	0
Adverse effects of lidocaine*	0	0

***** potential adverse effects of lidocaine are tinnitus, blurred vision of double vision and metal taste